There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Diamedica Therapeutics (DMAC – Research Report), Inspire Medical Systems (INSP – Research Report) and Maravai Lifesciences Holdings (MRVI – Research Report) with bullish sentiments.
Diamedica Therapeutics (DMAC)
Lake Street analyst Thomas Flaten maintained a Buy rating on Diamedica Therapeutics today and set a price target of $7.00. The company’s shares closed last Wednesday at $2.60.
According to TipRanks.com, Flaten has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Diamedica Therapeutics is a Strong Buy with an average price target of $7.00.
See today’s best-performing stocks on TipRanks >>
Inspire Medical Systems (INSP)
Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems today and set a price target of $270.00. The company’s shares closed last Wednesday at $243.51.
According to TipRanks.com, Takkinen is a 3-star analyst with an average return of
Currently, the analyst consensus on Inspire Medical Systems is a Strong Buy with an average price target of $250.67, representing a 9.9% upside. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $250.00 price target.
Maravai Lifesciences Holdings (MRVI)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Maravai Lifesciences Holdings today. The company’s shares closed last Wednesday at $7.73.
According to TipRanks.com, Hewitt has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Maravai Lifesciences Holdings is a Strong Buy with an average price target of $10.25, a 25.2% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DMAC:
